A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)
Clinical trial NCT04234607 · UNKNOWN
Trial details
- NCT number
- NCT04234607
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2020-01-01
- Primary completion
- 2022-12-01
- Enrollment
- 738
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.